高级搜索
伊立替康周疗法治疗转移性大肠癌的临床观察[J]. 肿瘤防治研究, 2005, 32(02): 110-112. DOI: 10.3971/j.issn.1000-8578.1199
引用本文: 伊立替康周疗法治疗转移性大肠癌的临床观察[J]. 肿瘤防治研究, 2005, 32(02): 110-112. DOI: 10.3971/j.issn.1000-8578.1199
Clinical Study of Weekly Irinotecan in Patients with Metastatic Colorectal Cancer[J]. Cancer Research on Prevention and Treatment, 2005, 32(02): 110-112. DOI: 10.3971/j.issn.1000-8578.1199
Citation: Clinical Study of Weekly Irinotecan in Patients with Metastatic Colorectal Cancer[J]. Cancer Research on Prevention and Treatment, 2005, 32(02): 110-112. DOI: 10.3971/j.issn.1000-8578.1199

伊立替康周疗法治疗转移性大肠癌的临床观察

Clinical Study of Weekly Irinotecan in Patients with Metastatic Colorectal Cancer

  • 摘要: 目的 评价伊立替康(CPT-11)联合CF/5-Fu周疗法治疗转移性大肠癌的疗效及毒性反应。方法 转移性大肠癌患者,给予CPT-11 125mg/m^2,5-Fu 500mg/m^2.CF200mg/m^2;均为每周1次.连用4周,休息2周.即6周时间为1周期;至少应用2周期。以WHO、NCI标准分别对有效性和安全性进行评价。结果 全组24例共进行97周期,平均4周期;获得PR4例.SD11例.PD9例;有效率为16.7%。中位缓解期5个月;中位疾病进展时间6个月;中位生存期11个月。该方案的毒性反应较轻微,Ⅲ度毒性主要是食欲下降3例,恶心呕吐4例.延迟性腹泻3例.腹痛2例。未发生Ⅳ度毒性。结论 CPT-11为主联合CF/5-Fu周疗法治疗转移性大肠癌疗效肯定.毒性反应降低.是治疗转移性大肠癌的有效而安全的方案。

     

    Abstract: Objective  To evaluate the efficacy and toxicity of weekly irinotecan combining with CF/ 5-Fu in the domastic patient s with metastatic colorectal cancer. Methods  CPT-11 125mg/ m2 ,5-Fu 500mg/ m2, CF 200mg/ m2 ;which were used for 4 weeks and ret reated af ter 2 weeks, that was one cycle consisted of 6 weeks. WHO、NCI criterion were used to evaluation. Results  The 24 patient s with metastatic colorectal cancer were enrolled in this study. Gross efficiency rate was 16. 7 % with 4 cases of PR. The median respond time was 5 months, median time to progression was 6 months, and the median survival time was 11months. Toxic effect s were light . There was no severe delayed diarrhea. Conclusion  The chemotherapy regimen mentioned above had better effective and less toxic effect s, suitable for the metastatic colorectal cancer.

     

/

返回文章
返回